No evidence of durable trained immunity after two doses of adenovirus-vectored or mRNA COVID-19 vaccines

Ítems similars

• 749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
  per: Marco Donia, et al.
  Publicat: (2023-11-01)
• Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma
  per: Tine J. Monberg, et al.
  Publicat: (2025-03-01)
• An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage
  per: Santeri Pakola, et al.
  Publicat: (2023-07-01)
• 739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial
  per: Tuomo Alanko, et al.
  Publicat: (2023-11-01)
• 711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials
  per: Tuomo Alanko, et al.
  Publicat: (2023-11-01)